Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. (NASDAQ: NKTX) is a clinical-stage biotechnology and biopharmaceutical company developing engineered natural killer (NK) cell therapies, with a stated focus on allogeneic, off-the-shelf NK cell therapies for autoimmune diseases. The NKTX news page on Stock Titan aggregates company press releases and market-moving updates so readers can follow how Nkarta’s NK cell platform and clinical programs progress over time.
Nkarta’s news flow frequently centers on clinical milestones for its lead candidate NKX019, including enrollment updates, protocol amendments, and dose-escalation decisions in the Ntrust-1 and Ntrust-2 autoimmune disease trials. The company also issues releases on investigator-sponsored trials of NKX019 in generalized myasthenia gravis and systemic lupus erythematosus, as well as presentations of clinical and preclinical data at scientific meetings such as rheumatology conferences.
Investors and observers can also find quarterly financial results and corporate highlights in Nkarta’s news, which summarize research and development spending, general and administrative expenses, net loss, and the company’s stated cash runway. These updates often include commentary on restructuring efforts, leadership changes in clinical and research roles, and Nkarta’s plans for future data disclosures from its NKX019 programs.
In addition, Nkarta regularly announces participation in healthcare and investor conferences, where management discusses the company’s NK cell platform, autoimmune focus, and clinical strategy. For anyone tracking NKTX stock, this news page offers a centralized view of Nkarta’s scientific, clinical, financial, and corporate developments related to its engineered NK cell therapies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nkarta, Inc. (Nasdaq: NKTX) reported its Q1 2023 financial results and corporate highlights. The company, focused on developing engineered natural killer (NK) cell therapies, announced:
1. Clinical updates for NKX101 expected in Q2 2023 and NKX019 in H2 2023.
2. Cash and cash equivalents of $332.1 million as of March 31, 2023.
3. Cash runway anticipated to fund operations into 2025.
4. Net loss of $30.8 million, or $0.63 per share, for Q1 2023.
5. R&D expenses of $26.1 million and G&A expenses of $8.2 million for Q1 2023.
The company plans to present additional clinical data for both NKX101 and NKX019 in their respective ongoing Phase 1 trials. Nkarta also announced the resignation of its CFO and business officer, Nadir Mahmood, PhD, effective June 30, 2023.
Summary not available.
Nkarta, Inc. (Nasdaq: NKTX) presented groundbreaking preclinical data at the 2023 AACR Annual Meeting, highlighting the enhanced efficacy of engineered natural killer (NK) cell therapies. The studies showcased the combination of NKX101, targeting the NKG2D receptor, with the monoclonal antibody cetuximab, leading to significant improvements in cancer cell killing in vitro. Additionally, researchers demonstrated that ADAM17 gene knockout in NK or CAR NK cells enhances antibody-dependent cellular cytotoxicity (ADCC) and overall anti-tumor activity. These findings emphasize the potential of NKX101 and ADAM17 KO therapies in treating solid tumors, marking a critical step toward clinical application. The studies support further exploration of NK cell therapies combined with therapeutic antibodies for improved anti-tumor treatments.
Nkarta, a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, announced its participation in two investor conferences:
- 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 3:00 p.m. ET - featuring a fireside chat.
- Canaccord Genuity Horizons in Oncology Virtual Conference on April 20, 2023, at 3:00 p.m. ET - featuring a panel discussion.
Webcasts of these events will be available on the Investors section of Nkarta's website, with replays archived for approximately 90 days. Nkarta specializes in off-the-shelf NK cell therapies aimed at providing broad access and deep anti-tumor activity in outpatient settings, utilizing advanced cell engineering technologies.
Nkarta, Inc. (NASDAQ: NKTX) announced that its CFO, Nadir Mahmood, PhD, has resigned to become CEO of another biotech firm, remaining until June 30, 2023, to ensure a smooth transition. Nkarta is on schedule to release updated results from its NKX101 clinical trial in Q2 2023 and is initiating external searches for a new CFO. This transition follows Mahmood's five years at Nkarta, highlighted by his contributions to advancing NK cell therapies aimed at treating cancer. Nkarta remains focused on developing its pipeline and maintaining progress in clinical trials.
Nkarta, Inc. (Nasdaq: NKTX) reported its financial results for Q4 and the full year 2022, highlighting a net loss of $113.8 million or $2.61 per share. As of December 31, 2022, the company had cash and equivalents of $354.9 million, projected to fund operations into 2025. Nkarta is advancing its NKX101 and NKX019 therapies, with clinical updates expected in 2023. NKX101 showed a 60% complete response rate in r/r AML patients, while NKX019 demonstrated a 70% complete response in relapsed/refractory B-cell malignancies. Both therapies appear well-tolerated, with no significant toxicity reported.